The anti-interleukin agent romilkimab showed significant benefits on skin fibrosis among patients with systemic sclerosis in a phase II trial, researchers reported. At week 24, the least squares mean ...

Juno Therapeutics, a subsidiary of Bristol Myers ( BMY) Squibb, was granted FDA orphan designation for its treatment of ...

New genetic evidence links higher BMI and IBD to hidradenitis suppurativa risk, while smoking remains unclear. Read more.

Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy ...

It can be a real pain in the neck. Rheumatoid arthritis, or RA, is an autoimmune disease in which the body mistakenly attacks ...

Shares of CRISPR Therapeutics CRSP were up 3.7% yesterday after the company announced encouraging updates from ongoing ...

CRISPR Therapeutics (NASDAQ:CRSP) is one of the best emerging technology stocks to invest in. On December 22, CRISPR Therapeutics released a comprehensive clinical update on zugocaptagene geleucel ...

Refractory dry eye in patients with systemic comorbidities can be challenging to manage because the underlying condition or ...

The FDA has approved Jascayd (nerandomilast) as a treatment for a second lung disease, progressive pulmonary fibrosis, following the drug’s initial approval in October 2025 as a treatment for ...

As of Wednesday, December 17, Kyverna Therapeutics, Inc.’s KYTX share price has dipped by 29.30%, which has investors questioning if this is right time to buy.

Immunotherapy has emerged in recent years as a new cancer treatment that is gentler than traditional chemotherapy and causes ...

Asal Shirazi, Founder of ASA Foundation, shares insights into what drives inflammatory responses, including the role of ...